UNSPSC 51412016: Nanterinone mesylate

This classification denotes a phosphodiesterase inhibitor with the molecular formula C15H15N3O.CH4O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier O345A477QI, chemically known as 2(1h)-quinolinone, 6-(2,4-dimethyl-1h-imidazol-1-yl)-8-methyl-, methanesulfonate (1:1), but more generally known as nanterinone mesylate, which bears US NIH Compound Identifier 92089. European Medicines Agency schedules nanterinone mesylate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09150MIG.

Most nations, for tariff purposes, schedule nanterinone mesylate under HS 29337900. SMILES: CC1CC(CC2C1[NH]C(=O)CC2)N3CC(NC3C)C.CS(=O)(=O)O.

UNSPSC 51412016 Nanterinone mesylate, a Commodity code, reflects state and local procurement of emergency response and clinical medications, though the available recent opportunities show limited direct sourcing activity under this specific drug identifier. State and local governments acquire advanced life support medications, generic pharmaceuticals, and over-the-counter products through city fire-rescue departments, state health agencies, and multi-state cooperative purchasing alliances. The work encompasses sealed-bid procurement of specific medication line items with strict expiration-date requirements, compliance with OSHA and FDA standards, and multi-year framework agreements through cooperative purchasing vehicles. Issuing bodies include city purchasing departments handling emergency medical supply contracts, state health and human services commissions managing pharmacy benefit initiatives, and regional cooperative purchasing organizations aggregating demand across state and local members.

Activity under the code concentrates in Florida and Minnesota, with Texas representing emerging procurement through exploratory market-research mechanisms. The City of Tampa's Purchasing Department issued IFB 26P00188 on April 24, 2026, for Advanced Life Support Medications to supply Tampa Fire Rescue, with sealed bids due April 8, 2026, under a one-year term valued at $40,000 and offering a 5 percent bid discount for Small Local Business Enterprise participation. The Minnesota Department of Administration's Office of State Procurement, administering the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), issued RFP S1070000015802 on January 20, 2026, for generic multi-source pharmaceuticals and OTC products distributed across participating state and local facilities in Minnesota and Oregon, with proposals due March 26, 2026, and evaluation weighted 75 percent on price competitiveness. The Texas Health and Human Services Commission issued exploratory RFI HHS0017013 in late March 2026 to gauge vendor capability for direct-to-manufacturer prescription programs, signaling potential future formal solicitation in the state pharmacy market.